A Phase III, Double-Blinded, Multicenter,
Randomized Study Evaluating The Efficacy and Safety of Neo-adjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer, NCT03456063
PURPOSE OF THIS CLINICAL RESEARCH TRIAL:
This is a randomized, double-blinded study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in patients with resectable Stage II, IIIA, or select IIIB non−small cell lung cancer (NSCLC) followed by open-label adjuvant atezolizumab or best supportive care and monitoring.
MORE DETAILS ON THIS TRIAL:
17140 / NCT03456063 / Open 3-30-2018
TRIAL AVAILABLE AT THE FOLLOWING LOCATIONS:
All RMCC Locations